img

Global Spinal Muscular Atrophy Industry Outlook 2024: Overview, Opportunities, Key Companies and Forecast to 2034


Published on: 2024-01-04 | No of Pages : 320 | Industry : Medical Care

Publisher : GRD Survey | Format : PDF

Global Spinal Muscular Atrophy Industry Outlook 2024: Overview, Opportunities, Key Companies and Forecast to 2034

Executive Summary

According to GRD Survey data, the global Spinal Muscular Atrophy market is estimated at million US$ in 2021 and is expected to million US$ by the end of 2028, growing at a CAGR of % in the forecast period from 2022 to 2028.

This report studies the Spinal Muscular Atrophy market dynamics from angles such as new entries, mergers and acquisitions, fundings, exit and major technology breakthroughs. Market performance is evaluated through market size (Million USD) by players, regions, product types and end industries. This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.

Geographically, this report is segmented into several key regions, with revenue, market share and growth Rate of Spinal Muscular Atrophy in these regions, from 2016 to 2027, covering
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Italy, Spain and Russia, etc.)
Asia-Pacific (China, Japan, Korea, Southeast Asia, India, Australia)
South America (Brazil, Argentina, Colombia, etc.)
Middle East and Africa (Turkey, Saudi Arabia, South Africa, etc.)

Market Snapshot, By Product Type
Early Stage Candidates
Late Stage Candidates

Market Snapshot, By Application
Hospital
Clinic
Others

Main Market Players Analyzed in this report, including
Novartis
Lonis Pharmaceuticals
Ionis Pharmaceuticals
F. Hoffmann-La Roche
Cytokinetics
AveXis

The study objectives of this report are
To study and analyze the global Spinal Muscular Atrophy market size (Million USD) by company, key regions/countries, products and application, history data from 2016 to 2020, and forecast to 2027.
To understand industry structure of Spinal Muscular Atrophy market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To identify the key global Spinal Muscular Atrophy manufacturers and regional typical players, to define, describe and analyze their sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Spinal Muscular Atrophy market with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Spinal Muscular Atrophy submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Spinal Muscular Atrophy are as follows
History Year2016-2020
Base Year2020
Estimated Year2021
Forecast Year 2021 to 2027

This report includes the estimation of market size from top-down approach by analyzing major submarkets and their major driving factors, and verified from bottom-up approaches. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified from primary sources.

For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders Considered in the study
Raw material vendors
Distributors/traders/wholesalers/suppliers
Regulatory authorities, including government agencies and NGO
Commercial research & development (R&D) institutions
Importers and exporters
Government organizations, research organizations, and consulting firms
Trade/Industrial associations
End-use industries

Table of Content

Table of Contents

1 Market Definition & Scope
1.1 Definition & Scope
1.2 Spinal Muscular Atrophy Product Specifications
1.3 Main Events (Entry, M&A, Exit, Technology and Capital Activity)
1.4 Global Spinal Muscular Atrophy Market Performance and Outlook

2 Market Development Performance under COVID-19
2.1 Influencing Factors of Industry Development in the Next Five Years
2.1.1 Drivers
2.1.2 Restraints
2.1.3 Opportunities
2.2 Porter’s Five Forces Analysis
2.3 Comparison of Alternatives and Spinal Muscular Atrophy

3 3 Industrial Lift Cycle and Main Buyers Analysis
3.1 Industry Life Cycle Analysis
3.2 Key Buying Industries/Consumers
3.2.1 Major Buyers in Hospital
3.2.2 Major Buyers in Clinic

4 Market Segment: by Type
4.1 Spinal Muscular Atrophy Type Introduction
4.1.1 Early Stage Candidates
4.1.2 Late Stage Candidates
4.2 Global Spinal Muscular Atrophy Revenue by Type 2016-2021

5 Market Segment: by Application
5.1 Spinal Muscular Atrophy Type Introduction
5.1.1 Hospital
5.1.2 Clinic
5.1.3 Others
5.2 Global Spinal Muscular Atrophy Revenue by Application 2016-2021

6 Marke Segment: by Region
6.1 Global Spinal Muscular Atrophy Market by Region
6.2 North America Spinal Muscular Atrophy Market 2016-2021
6.3 Europe Spinal Muscular Atrophy Market 2016-2021
6.4 Asia Pacific Spinal Muscular Atrophy Market 2016-2021
6.5 South America Spinal Muscular Atrophy Market 2016-2021
6.6 Middle East and Africa Spinal Muscular Atrophy Market 2016-2021

7 North America
7.1 North America Spinal Muscular Atrophy Market by Country 2016-2021
7.2 United States
7.3 Canada
7.4 Mexico

8 Europe
8.1 Europe Spinal Muscular Atrophy Market by Country 2016-2021
8.2 Germany
8.3 France
8.4 UK
8.5 Italy
8.6 Russia
8.7 Spain

9 Asia Pacific
9.1 Asia Pacific Spinal Muscular Atrophy Market by Country 2016-2021
9.2 China
9.3 Japan
9.4 Korea
9.5 Southeast Asia
9.6 India
9.7 Australia

10 South America
10.1 South America Spinal Muscular Atrophy Market by Country 2016-2021
10.2 Brazil
10.3 Argentina
10.4 Colombia

11 Middle East and Africa
11.1 Middle East and Africa Spinal Muscular Atrophy Market by Country 2016-2021
11.2 Turkey
11.3 Saudi Arabia
11.4 South Africa

12 Key Participants Company Information
12.1 Novartis
12.1.1 Novartis Company Information
12.1.2 Novartis Spinal Muscular Atrophy Product Portfolio, Specification and Application
12.1.3 Novartis Spinal Muscular Atrophy Revenue and Gross Margin (2019-2021)
12.1.4 Novartis Key Development
12.2 Lonis Pharmaceuticals
12.2.1 Lonis Pharmaceuticals Company Information
12.2.2 Lonis Pharmaceuticals Spinal Muscular Atrophy Product Portfolio, Specification and Application
12.2.3 Lonis Pharmaceuticals Spinal Muscular Atrophy Revenue and Gross Margin (2019-2021)
12.2.4 Lonis Pharmaceuticals Key Development
12.3 Ionis Pharmaceuticals
12.3.1 Ionis Pharmaceuticals Company Information
12.3.2 Ionis Pharmaceuticals Spinal Muscular Atrophy Product Portfolio, Specification and Application
12.3.3 Ionis Pharmaceuticals Spinal Muscular Atrophy Revenue and Gross Margin (2019-2021)
12.3.4 Ionis Pharmaceuticals Key Development
12.4 F. Hoffmann-La Roche
12.4.1 F. Hoffmann-La Roche Company Information
12.4.2 F. Hoffmann-La Roche Spinal Muscular Atrophy Product Portfolio, Specification and Application
12.4.3 F. Hoffmann-La Roche Spinal Muscular Atrophy Revenue and Gross Margin (2019-2021)
12.4.4 F. Hoffmann-La Roche Key Development
12.5 Cytokinetics
12.5.1 Cytokinetics Company Information
12.5.2 Cytokinetics Spinal Muscular Atrophy Product Portfolio, Specification and Application
12.5.3 Cytokinetics Spinal Muscular Atrophy Revenue and Gross Margin (2019-2021)
12.5.4 Cytokinetics Key Development
12.6 AveXis
12.6.1 AveXis Company Information
12.6.2 AveXis Spinal Muscular Atrophy Product Portfolio, Specification and Application
12.6.3 AveXis Spinal Muscular Atrophy Revenue and Gross Margin (2019-2021)
12.6.4 AveXis Key Development

13 Global Spinal Muscular Atrophy Market Forecast by Region by Type and by Application
13.1 Global Spinal Muscular Atrophy Revenue Forecast 2022-2027
13.2 Global Spinal Muscular Atrophy Forecast by Regions
13.3 Global Spinal Muscular Atrophy Forecast by Type
13.4 Global Spinal Muscular Atrophy Forecast by Application

14 Analyst Views and Conclusions

15 Methodology and Data Source
15.1 Methodology
15.2 Research Data Source
15.2.1 Secondary Data
15.2.2 Primary Data
15.2.3 Market Size Estimation
15.3 Legal Disclaimer

List of Figure

List of Tables

Table 1: Global Spinal Muscular Atrophy Production Specifications
Table 2: Drivers in Spinal Muscular Atrophy Market
Table 3: Restraints Spinal Muscular Atrophy Market
Table 4: Opportunity in Spinal Muscular Atrophy Market
Table 5: Comparion of Alternative and Spinal Muscular Atrophy
Table 6: Spinal Muscular Atrophy Raw Materials Key Suppliers List
Table 7: Spinal Muscular Atrophy Distributors List
Table 8: Spinal Muscular Atrophy Major Buyers in Application One
Table 9: Spinal Muscular Atrophy Major Buyers in Application Two
Table 10: Spinal Muscular Atrophy Major Buyers in Application Three
Table 11: Global Spinal Muscular Atrophy Revenue (Million USD) by Type 2016-2021
Table 12: Global Spinal Muscular Atrophy Revenue Market Share by Type 2016-2021
Table 18: Global Spinal Muscular Atrophy Revenue (Million USD) by Application 2016-2021
Table 19: Global Spinal Muscular Atrophy Revenue Market Share by Application 2016-2021
Table 20: Global Spinal Muscular Atrophy Revenue (Million USD) by Region 2016-2021
Table 21: Global Spinal Muscular Atrophy Revenue Market Share by Region 2016-2021
Table 22: North America Spinal Muscular Atrophy Revenue (Million USD) by Country 2016-2021
Table 23: North America Spinal Muscular Atrophy Revenue Market Share by Country 2016-2021)
Table 24: Europe Spinal Muscular Atrophy Revenue (Million USD) by Country 2016-2021
Table 25: Europe Spinal Muscular Atrophy Revenue Market Share by Country 2016-2021)
Table 26: Asia Pacific Spinal Muscular Atrophy Revenue (Million USD) by Country 2016-2021
Table 27: Asia Pacific Spinal Muscular Atrophy Revenue Market Share by Country 2016-2021)
Table 28: South America Spinal Muscular Atrophy Revenue (Million USD) by Country 2016-2021
Table 29: South America Spinal Muscular Atrophy Revenue Market Share by Country 2016-2021)
Table 30: Middle East and Africa Spinal Muscular Atrophy Revenue (Million USD) by Country 2016-2021
Table 31: Middle East and Africa Spinal Muscular Atrophy Revenue Market Share by Country 2016-2021)
Table 32 Novartis Company Information
Table 33 Novartis Spinal Muscular Atrophy Product Portfolio, Specification and Application
Table 34 Novartis Spinal Muscular Atrophy Revenue and Gross Margin (2019-2021)
Table 35 Lonis Pharmaceuticals Company Information
Table 36 Lonis Pharmaceuticals Spinal Muscular Atrophy Product Portfolio, Specification and Application
Table 37 Lonis Pharmaceuticals Spinal Muscular Atrophy Revenue and Gross Margin (2019-2021)
Table 38 Ionis Pharmaceuticals Company Information
Table 39 Ionis Pharmaceuticals Spinal Muscular Atrophy Product Portfolio, Specification and Application
Table 40 Ionis Pharmaceuticals Spinal Muscular Atrophy Revenue and Gross Margin (2019-2021)
Table 41 F. Hoffmann-La Roche Company Information
Table 42 F. Hoffmann-La Roche Spinal Muscular Atrophy Product Portfolio, Specification and Application
Table 43 F. Hoffmann-La Roche Spinal Muscular Atrophy Revenue and Gross Margin (2019-2021)
Table 44 Cytokinetics Company Information
Table 45 Cytokinetics Spinal Muscular Atrophy Product Portfolio, Specification and Application
Table 46 Cytokinetics Spinal Muscular Atrophy Revenue and Gross Margin (2019-2021)
Table 47 AveXis Company Information
Table 48 AveXis Spinal Muscular Atrophy Product Portfolio, Specification and Application
Table 49 AveXis Spinal Muscular Atrophy Revenue and Gross Margin (2019-2021)
Table 59: Global Spinal Muscular Atrophy Revenue (Million USD) Forecast by Region (2022-2027)
Table 60: Global Spinal Muscular Atrophy Revenue Market Share Forecast by Region (2022-2027)
Table 61: Global Spinal Muscular Atrophy Revenue (Million USD) Forecast by Type (2022-2027)
Table 62: Global Spinal Muscular Atrophy Revenue Market Share Forecast by Type (2022-2027)
Table 63: Global Spinal Muscular Atrophy Revenue (Million USD) Forecast by Application (2022-2027)
Table 64: Global Spinal Muscular Atrophy Revenue Market Share Forecast by Application (2022-2027)


List of Figures

Figure 1: Spinal Muscular Atrophy Picture
Figure 2: Global Spinal Muscular Atrophy Market Size (Million USD) and Growth Rate (2016-2027)
Figure 3: Porter's Five Forces Analysis
Figure 4: Spinal Muscular Atrophy Industry Life Cycle
Figure 5: Product Picture of Early Stage Candidates
Figure 6: Product Picture of Late Stage Candidates
Figure 9: Global Spinal Muscular Atrophy Revenue Market Share by Type, 2020
Figure 10: Spinal Muscular Atrophy in Hospital
Figure 11: Global Spinal Muscular Atrophy Market: Hospital 2016-2021
Figure 12: Spinal Muscular Atrophy in Clinic
Figure 13: Global Spinal Muscular Atrophy Market: Clinic 2016-2021
Figure 14: Global Spinal Muscular Atrophy Revenue Market Share by Application, 2020
Figure 15: Global Spinal Muscular Atrophy Revenue Market Share by Region 2016-2021
Figure 16: North America Spinal Muscular Atrophy Revenue (Million USD) Status 2016-2021
Figure 7: Europe Spinal Muscular Atrophy Revenue (Million USD) Status 2016-2021
Figure 8: Asia Pacific Spinal Muscular Atrophy Revenue (Million USD) Status 2016-2021
Figure 9: South America Spinal Muscular Atrophy Revenue (Million USD) Status 2016-2021
Figure 10: Middle East and Africa Spinal Muscular Atrophy Revenue (Million USD) Status 2016-2021
Figure 11: North America Spinal Muscular Atrophy Revenue Market Share by Country, 2020
Figure 12: United States Spinal Muscular Atrophy Revenue (Million USD) Status 2016-2021
Figure 13: Canada Spinal Muscular Atrophy Revenue (Million USD) Status 2016-2021
Figure 14: Mexico Spinal Muscular Atrophy Revenue (Million USD) Status 2016-2021
Figure 15: Europe Spinal Muscular Atrophy Revenue Market Share by Country, 2020
Figure 16: Germany Spinal Muscular Atrophy Revenue (Million USD) Status 2016-2021
Figure 17: France Spinal Muscular Atrophy Revenue (Million USD) Status 2016-2021
Figure 18: UK Spinal Muscular Atrophy Revenue (Million USD) Status 2016-2021
Figure 19: Italy Spinal Muscular Atrophy Revenue (Million USD) Status 2016-2021
Figure 20: Russia Spinal Muscular Atrophy Revenue (Million USD) Status 2016-2021
Figure 21: Spain Spinal Muscular Atrophy Revenue (Million USD) Status 2016-2021
Figure 22: Asia Pacific Spinal Muscular Atrophy Revenue Market Share by Country, 2020
Figure 23: China Spinal Muscular Atrophy Revenue (Million USD) Status 2016-2021
Figure 24: Japan Spinal Muscular Atrophy Revenue (Million USD) Status 2016-2021
Figure 25: Korea Spinal Muscular Atrophy Revenue (Million USD) Status 2016-2021
Figure 26: Southeast Asia Spinal Muscular Atrophy Revenue (Million USD) Status 2016-2021
Figure 27: India Spinal Muscular Atrophy Revenue (Million USD) Status 2016-2021
Figure 28: Australia Spinal Muscular Atrophy Revenue (Million USD) Status 2016-2021
Figure 29: South America Spinal Muscular Atrophy Revenue Market Share by Country, 2020
Figure 30: Brazil Spinal Muscular Atrophy Revenue (Million USD) Status 2016-2021
Figure 31: Argentina Spinal Muscular Atrophy Revenue (Million USD) Status 2016-2021
Figure 32: Colombia Spinal Muscular Atrophy Revenue (Million USD) Status 2016-2021
Figure 33: Middle East and Africa Spinal Muscular Atrophy Revenue Market Share by Country, 2020
Figure 34: Turkey Spinal Muscular Atrophy Revenue (Million USD) Status 2016-2021
Figure 35: Saudi Arabia Spinal Muscular Atrophy Revenue (Million USD) Status 2016-2021
Figure 36: South Africa Spinal Muscular Atrophy Revenue (Million USD) Status 2016-2021
Figure 37: Novartis Spinal Muscular Atrophy Revenue Market Share Globally (2019-2021)
Figure 38: Lonis Pharmaceuticals Spinal Muscular Atrophy Revenue Market Share Globally (2019-2021)
Figure 39: Ionis Pharmaceuticals Spinal Muscular Atrophy Revenue Market Share Globally (2019-2021)
Figure 40: F. Hoffmann-La Roche Spinal Muscular Atrophy Revenue Market Share Globally (2019-2021)
Figure 41: Cytokinetics Spinal Muscular Atrophy Revenue Market Share Globally (2019-2021)
Figure 42: AveXis Spinal Muscular Atrophy Revenue Market Share Globally (2019-2021)
Figure 47: Global Spinal Muscular Atrophy Revenue (Million USD) Forecast (2022-2027)